Engaging a Regulatory Affairs Consultant before submitting to major agencies like the FDA (U.S.), EMA (Europe), or CDSCO (India) is a smart move for pharmaceutical, biotech, or medical device companies. The right consultant can spot gaps, refine your strategy, and boost approval odds—while the wrong one might lead to delays, extra costs, or rejection.
Before committing, ask targeted questions to evaluate their expertise, track record, approach, and fit for your specific product and target markets. These questions help assess if they truly understand your therapeutic area, submission type (e.g., NDA, BLA, 510(k), PMA, MAA, or Indian NDCTR), and the nuances of each agency’s expectations.
Here are the top 5 critical questions to ask a Regulatory Affairs Consultant before your FDA, EMA, or CDSCO submission:
- What is your direct experience with successful submissions similar to my product in the target agencies (FDA, EMA, CDSCO)? Probe for specifics: Which therapeutic areas or device classes have you handled? How many NDAs, BLAs, 510(k)s, PMAs, MAAs, or CDSCO registrations have you led to approval in the last 5 years? Ask for anonymized examples or success rates. A strong consultant should provide evidence of navigating the exact pathway you’re pursuing—e.g., Breakthrough Therapy designation for FDA, PRIME for EMA, or fast-track options in India. This reveals if they have recent, relevant hands-on wins rather than just general knowledge.
- How would you assess and address potential gaps in our current development program and dossier before submission? This tests their proactive, gap-analysis approach. Expect them to mention conducting a thorough review of CMC (quality), non-clinical, clinical data, risk management, and labeling against current guidelines (ICH, FDA/EMA/CDSCO specifics). Ask how they handle common pitfalls like inadequate stability data, unresolved impurities, weak endpoints, or manufacturing validation issues. A good response includes plans for pre-submission meetings (e.g., FDA Pre-IND/Pre-Submission, EMA Scientific Advice, or CDSCO consultations) to de-risk early.
- What is your strategy for agency interactions, including pre-submission meetings, responding to queries, and managing timelines? Consultants should outline how they prepare briefing packages, craft precise questions for agencies, and facilitate productive interactions. Inquire about their experience with RFIs (Requests for Information), deficiency letters, or major objections—and how they minimize back-and-forth. For multi-region strategies, ask how they align submissions across FDA, EMA (e.g., via centralized procedure), and CDSCO while handling differences in requirements (like pediatric plans or local testing in India). This shows their ability to keep your project on track and avoid prolonged reviews.
- How do you stay current with evolving regulations, guidelines, and agency expectations in our field? Regulatory landscapes shift frequently—new ICH updates, FDA guidance on real-world evidence, EMA adaptive pathways, or CDSCO’s evolving medical device rules under MDR 2017. Ask about their sources (e.g., subscriptions to FDA/EMA alerts, RAPS/DIA involvement, peer networks) and how they incorporate changes into client strategies. Look for evidence of recent training, publications, or adaptations to post-2020 updates like digital submissions (eCTD 4.0) or supply chain resilience focus.
- What is your approach to collaboration with our internal teams, and what are your fees, timelines, and success metrics for this engagement? Clarify how they integrate with your cross-functional team (clinical, CMC, quality, legal) to avoid silos. Discuss deliverables (gap reports, submission roadmaps, mock reviews), communication frequency, and escalation processes. On the business side, get clear details: fixed vs. hourly fees, milestones, estimated hours for your scope, and how they measure success (e.g., first-cycle approval, minimal queries). This ensures alignment on expectations and prevents surprises.
Asking these questions upfront helps you select a consultant who brings proven expertise, strategic foresight, and a partnership mindset—ultimately saving time, reducing risks, and improving your chances of a smooth approval in competitive regulatory environments.
Follow us on X @realnewshubs and subscribe for push notifications.
Sam Michael